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Background: Nanoparticle-based systems are promising for the development of imaging 
and therapeutic agents. The main advantage of nanoparticles over traditional systems lies in 
the possibility of loading multiple functionalities onto a single molecule, which are useful for 
therapeutic and/or diagnostic purposes. These functionalities include targeting moieties which 
are able to recognize receptors overexpressed by specific cells and tissues. However, targeted 
delivery of nanoparticles requires an accurate system design. We present here a rationally 
designed, genetically engineered, and chemically modified protein-based nanoplatform for 
cell/tissue-specific targeting.
Methods: Our nanoparticle constructs were based on the heavy chain of the human protein 
ferritin (HFt), a highly symmetrical assembly of 24 subunits enclosing a hollow cavity. HFt-based 
nanoparticles were produced using both genetic engineering and chemical functionalization 
methods to impart several functionalities, ie, the α-melanocyte-stimulating hormone peptide 
as a melanoma-targeting moiety, stabilizing and HFt-masking polyethylene glycol molecules, 
rhodamine fluorophores, and magnetic resonance imaging agents. The constructs produced 
were extensively characterized by a number of physicochemical techniques, and assayed for 
selective melanoma-targeting in vitro and in vivo.
Results: Our HFt-based nanoparticle constructs functionalized with the α-melanocyte-
stimulating hormone peptide moiety and polyethylene glycol molecules were specifically taken 
up by melanoma cells but not by other cancer cell types in vitro. Moreover, experiments in 
melanoma-bearing mice indicate that these constructs have an excellent tumor-targeting profile 
and a long circulation time in vivo.
Conclusion: By masking human HFt with polyethylene glycol and targeting it with an 
α-melanocyte-stimulating hormone peptide, we developed an HFt-based melanoma-targeting 
nanoplatform for application in melanoma diagnosis and treatment. These results could be of 
general interest, because the same strategy can be exploited to develop ad hoc nanoplatforms 
for specific delivery towards any cell/tissue type for which a suitable targeting moiety is 
available.
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Introduction
Development of multifunctional nanoparticles for nanomedicine applications, such 
as cell/tissue-specific delivery, biomedical imaging and therapy, has recently gained 
wide popularity.1–4 Various types of materials, including synthetic polymers and 
lipids, have been increasingly utilized as platforms for nanoparticle synthesis.1,5 
Despite the large number of bioconjugation techniques available, the attainment of 
multifunctional nanoprobes endowed with desired   bioactivity, targeting specificity, 
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and stability remains a challenge. Approaches using 
protein-cage structures, such as proteins belonging to the 
ferritin family, are novel and very promising.6,7 Apoferritin 
is a highly symmetrical multimeric protein consisting of 
24 subunits that self-assemble into a shell-like molecule 
enclosing a hollow cavity, with external and internal 
diameters of 12 nm and 8 nm, respectively.8,9 Ferritin 
structure and size are precisely controlled at the atomic 
level, because ferritin monomers are gene products. As a 
consequence, ferritin proteins guarantee excellent size and 
shape control in metal nanoparticle synthesis, and several 
materials, such as Fe3O4, Co3O4, Mn3O4, Pt, CoPt, Pd, 
CdS, CdSe, ZnSe, CaCO3, Ag, and Au have been produced 
within the internal cavity of ferritin proteins.10–18 The small 
size of ferritins (,20 nm) increases the chances of larger 
nanoparticles passing human body barriers and reaching 
specific targets. Indeed, the dimensions of the nanoparticles, 
which must be small enough to penetrate capillary 
fenestrations and large enough to avoid rapid clearance 
through the kidney (the ideal diameter being lower than 
50–60 nm and greater than 6–8 nm, respectively),19,20 are 
one of the key prerequisites for efficient targeted delivery, 
together with a long-circulating capability of the carrier 
and high specificity of the selector towards the target 
receptor. Additionally, the exceptional stability of the 
ferritin cage structure over a wide range of temperatures 
(up to 80°C–100°C) and pH conditions (3–10) and high 
expression levels as a recombinant protein in efficient 
heterologous systems like Escherichia coli cells (100–
200 mg/L in laboratory scale) allow the apoferritin protein 
to be produced on a large-scale, at high yield (gram or even 
kilogram) and at low cost, which is useful for industrial 
scaleup purposes. Further, human ferritin is a physiological 
protein that has high solubility and stability in water, 
blood, and buffers, as well as low toxicity, all of which are 
desirable features for in vivo applications in humans.21,22 
Several groups have reported that ferritins are effective 
templates for loading either imaging agents for magnetic 
resonance imaging or positron emission tomography 
(PET),21–24 as well as metal-based drugs in their internal 
cavity.25 Finally, ferritin proteins possess distinct interfaces 
(ie, an internal one facing the cavity and an external one 
facing the solvent) endowed with a variety of chemical 
groups, eg, primary amines, carboxylates, and thiols, which 
can be linked either genetically and/or chemically with 
different functionalities for targeted delivery of imaging 
and/or therapeutic agents.22,24 For all these reasons, there 
has been widespread interest in the possibility of using 
ferritin-based nanoplatforms for selective targeting.
In previous reports, the heavy chain of human ferritin 
(HFt) has been genetically conjugated with an arginine-
glycine-aspartate (RGD)-containing tumor targeting peptide, 
which is recognized by a large number of integrin molecules 
expressed by melanoma, glioma, and other tumors, as well 
as by normal cells.24,26 These RGD-containing HFt constructs 
have shown promising selectivity towards melanoma in in vitro 
experiments because compared with unconjugated HFt they 
have a threefold higher ability to bind melanoma cells, but 
show no difference in T lymphocyte binding.26 In spite of 
these encouraging results, only one study has reported on 
the application of HFt-based constructs bearing a targeting 
moiety for a physiological receptor in vivo.24 In this study, the 
localization of an RGD-containing HFt in an animal model 
of glioma was approximately 6% of the injected dosage, 2% 
of which was ascribed to the presence of the RGD targeting 
moiety and 4% to the enhanced permeability and retention 
effect of the tumor tissue. However, massive accumulation of 
the construct was observed in the liver, which appeared to be 
significantly greater than in the tumor.26
The enhanced permeability and retention effect has been 
shown to allow nanoparticles to accumulate at tumor sites 
in concentrations 5–10 times higher than in normal tissue 
within 1–2 days.27 However, this effect is counteracted both 
by fast clearance from plasma (10–60 minutes), which has 
been observed in rats, dogs, and rabbits after intravenous 
injection of liver ferritin, and by the presence of ferritin 
receptors on several cell types, including macrophages,21,28–32 
which determines ferritin removal from the circulation by the 
reticuloendothelial or mononuclear phagocytic systems.
To overcome these limitations and increase the circulation 
time of ferritin, as well as target specificity with respect to 
previously reported HFt constructs, we developed chemically 
and genetically engineered HFt-based nanoparticles aimed 
at specifically targeting melanoma cancer cells and tissues, 
while minimizing nonspecific binding versus other human 
cells (Scheme 1). To achieve these goals, the following 
strategy was adopted. First, HFt nanoparticles were 
genetically linked to α-melanocyte-stimulating hormone 
(α-MSH), which had not been exploited previously as a 
targeting moiety for HFt constructs. The MSH peptide 
binds to melanocortin receptors that are overexpressed by 
melanoma cells and metastases, and expressed to a lower 
extent only by melanocytes. As a consequence, it is expected 
to be significantly more selective than the RGD peptide 
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linked to HFt in previous studies, in that the RGD moiety is 
recognized by a large number of integrin molecules, which 
are expressed by both normal and tumor cells. Additionally, 
polyethylene glycol (PEG) molecules were conjugated with 
the HFt surface, with the aim of masking the protein from its 
physiological receptors. HFt masking by PEGylation, which 
has not been implemented in previous studies of HFt-based 
constructs, is aimed at decreasing uptake of HFt by the 
reticuloendothelial and mononuclear phagocytic systems, 
resulting in an increased blood circulation time.27 Moreover, 
PEGylation is an effective method for preventing putative 
responses by the immune system, which would be elicited if 
the nanoparticles were sensed as foreign agents, in spite of the 
fact that both the HFt protein and MSH peptide components 
are extracellular and of human origin.
To assess the targeting specificity of our HFt-MSH-
PEG constructs, we carried out in vitro experiments using 
both melanoma and control cells, with wild-type HFt and 
HFt-PEG as controls. Additionally, we investigated the 
  specificity and circulation time of the HFt-MSH-PEG 
  constructs in   melanoma-bearing mice, using wild-type HFt 
as a control.
The data reported herein demonstrate that the HFt-
MSH-PEG constructs were specifically taken up by 
  melanoma cells but not by other tumor cells in vitro, and that 
the ability of HFt-MSH-PEG to bind to, and be internalized 
by melanoma cells is significantly higher than that of HFt-
PEG nanoparticles, which are devoid of the targeting MSH 
moiety, and of wild-type HFt. If the MSH moiety endows 
HFt with melanoma-targeting ability, the presence of PEG 
efficiently shields HFt from its cell receptors, because the 
uptake of both HFt-PEG and HFt-MSH-PEG by colon cancer 
cells is significantly lower than that of wild-type HFt.
In agreement with our in vitro results, studies performed 
using a melanoma animal model in vivo showed that the 
HFt-MSH-PEG nanoparticles accumulated to a large extent 
at the tumor sites whereas accumulation of wild-type HFt 
was negligible, and that this accumulation effect appears 
Melanoma targeting
peptide (MSH)
Linker
Hollow
core
Melanoma cell
Melanoma targeting
Fluorescent ferritin
PEG
Iron
core
- Iron (magnetite)
- PEG-maleimide
- Rhodamine-NHS
Rhodamine
Scheme 1 Top: design of an HFt-based nanoplatform for melanoma targeting. The HFt protein has been genetically functionalized (left) with a melanocyte-stimulating 
hormone peptide joined to the N-terminus of each of the 24 subunits by a linker peptide (only five of the 24 derivatized N-termini are shown, for clarity). Additionally, 
chemical derivatization (right) has been performed to provide the HFt protein with novel functionalities for targeted delivery of imaging and therapeutic agents (polyethylene 
glycol, rhodamine, metal iron). Bottom: analysis of melanoma cells by confocal laser scanning microscopy. The shown confocal image demonstrates binding and uptake of 
HFt-based nanoparticles after in vitro incubation (60 minutes). 
Abbreviation: HFt, human protein ferritin.
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to be specific for the tumor when compared with the other 
tissues analyzed. Further, HFt-MSH-PEG had a higher 
circulation time than wild-type HFt, most likely because of 
the presence of PEG.
Thus, the strategy adopted to develop melanoma-targeting 
HFt-MSH-PEG nanoparticles appears to be suitable for 
the development of targeted imaging agents for magnetic 
resonance imaging, PET, and fluorescence imaging, as well as 
for targeted delivery of therapeutic agents in cancer therapy.
Materials and methods
Cloning, overexpression, and purification 
of HFt-based nanoparticles
The expression vector, pET-17b, containing the HFt-MSH 
gene, was purchased from GeneArt AG (Bavaria, Germany). 
Gene synthesis was performed taking into consideration the 
codon optimization for high level expression in E. coli. E. 
coli BL21 (DE3) cells harboring the recombinant HFt-MSH 
plasmid were grown to OD600 3.0 at 30°C in 1 L of ampicillin-
containing liquid Luria-Bertani broth medium (Sigma-Aldrich, 
Milan, Italy). The cells were harvested by centrifugation at 
16,000 rpm for 20 minutes and suspended in 50 mM Tris-HCl, 
0.5 mM dithiothreitol, 1 mM ethylenediamine tetra-acetic 
acid, and 300 mM NaCl at pH 7.5, and disrupted by sonication 
in the presence of 1 mM phenylmethylsulfonyl fluoride. The 
lysate was then centrifuged at 16,000 rpm for 40–45 minutes at 
6°C. The pellet was washed twice with 100 mM N-cyclohexyl-
3-aminopropanesulfonic acid (pH 10.5) and then centrifuged 
at 16,000 rpm for 10 minutes at 6°C to recover the HFt-
MSH protein from the membrane-containing fraction. After 
each centrifugation step, the supernatants were collected 
and combined with each other. The solution obtained was 
dialyzed overnight against Tris 30 mM, 0.6 M NaCl, pH 
7.8 at room temperature. HFt-MSH precipitates under these 
high salt conditions. The pellet was resuspended in Milli-Q 
water (Millipore, Billerica, MA), sterile-filtered, and stored 
at 4°C. Typical yields were 150–200 mg of pure protein per 
liter of culture. Human apo-HFt was provided by MoLiRom 
(Rome, Italy).
Protein stability measurements
The thermal stability of wild-type HFt and HFt-MSH was 
assessed in the temperature range of 30°C–100°C by following 
the circular dichroism signal at 222 nm to monitor the thermal 
unfolding process. A Jasco J-715 spectropolarimeter was 
used. Temperature was varied in steps of 1°C per minute. 
The protein, at 1 mg/mL in Milli-Q water, was kept in 
stoppered 0.1 cm quartz cells.
The ability of HFt-MSH to dissociate and reassociate 
reversibly as a function of pH was also assessed. The protein 
solution was adjusted to pH 2.0 by addition of HCl 0.1 M, and 
the pH was kept constant for about 15 minutes to ensure that 
dissociation of HFt-MSH was complete. The pH value was 
then adjusted to 7.5 by adding NaOH 0.1 M. The resulting 
solution was stirred at room temperature for 1 hour and 
checked for HFt-MSH oligomerization by size exclusion 
chromatography. The size exclusion chromatography 
experiments were performed using a Superose 6 gel filtration 
column connected to a GE Healthcare FPLC system Unicorn 
Akta purifier (GE Healthcare, Milan, Italy) equilibrated with 
phosphate-buffered saline at pH 7.5.
Preparation of PEGylated proteins
HFt and HFt-MSH solutions (2 mg/mL) were incubated with 
1.0 mM of 5 kDa methoxypolyethylene glycol maleimide 
(Sigma-Aldrich), in 20 mM Tris-HCl at pH 7.2 and room 
temperature for about 2 hours under stirring. Subsequently, 
samples were filtered and exchanged 4–5 times with H2Odd 
using 30 kDa Amicon Ultra-15 centrifugal filter devices 
(Millipore) to remove the excess reagents. The PEGylated 
samples were sterile-filtered and stored at 4°C.
Size exclusion chromatography and dynamic  
light scattering
The size exclusion chromatography experiments were 
performed using a Superose 6 gel filtration column 
equilibrated with phosphate-buffered saline at pH 7.5. 
Dynamic light scattering experiments were carried out using a 
Zetasizer Nano S (Malvern Instruments, Worcestershire, UK) 
equipped with a 4 mW He-Ne laser (633 nm). Measurements 
were performed at 25°C, with an angle of 173° from 
the incident beam. Peak intensity analyses were used to 
determine the average hydrodynamic diameters (Z-average 
diameter) of the scattering particles. Results are the average 
of at least five measurements. All samples were prepared at 
1 mg/mL in filtered H2Odd. All traces for the size exclusion 
chromatography and dynamic light scattering experiments 
were analyzed using Origin 8.0 (Originlab Corporation, 
Northampton, MA).
Mass spectrometric analysis and sample preparation
HFt-MSH and HFt-MSH-PEG samples at a concentration 
of 1 mg/mL were used in a native form and digested using 
trypsin enzyme (sequencing grade, Promega, Madison, WI). 
Trypsin digestion was performed overnight at 37°C in 25 mM 
ammonium bicarbonate at a pH of 8.0, with a trypsin:HFt 
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construct molar ratio of 1:50. The digested HFt construct 
was loaded onto the target plate and mixed immediately with 
an equal volume of α-cyanohydroxycinnamic acid in 50% 
acetonitrile and 0.1% trifluoroacetic acid (Sigma-Aldrich). 
The samples were analyzed using a matrix-assisted laser 
desorption/ionization (MALDI) time-of-flight Applied 
Biosystems/MDS Sciex 4800 Plus MALDI TOF/TOF™ 
analyzer (Monza, Italy). The base peak in the MALDI TOF 
mass spectrum (m/z 1056.5) was isolated and fragmented 
in the TOF/TOF mass spectrometer. Analysis of the tandem 
mass spectrum showed product ions (b and y series). Data 
analysis was carried out using the Data Explorer 4.0 software 
(Applied Biosystems).
Fourier transform infrared  
spectroscopic analysis
HFt-MSH and HFt-MSH-PEG samples for Fourier transform 
infrared spectroscopic measurements were used at 3 mg/mL 
in H2Odd and layered upon the ZnSe crystal. The protein solu-
tions (250 µL) were layered on the ZnSe plate, dried under a 
nitrogen stream, and placed in an atmosphere saturated with 
water vapor in a glove box for 24 hours in order to obtain a 
fully hydrated sample. Attenuated total reflectance–Fourier 
transform infrared spectroscopic   measurements were car-
ried out on a Magna 760 Nicolet instrument equipped with 
an MCT/A detector (ThermoFisher Scientific Inc, Illkirch 
Cedex, France). ZnSe ARK plates equipped with a thermal 
ARK temperature controller (ThermoFisher Scientific Inc) 
were used as internal reflection elements. A sealed, volatile 
solvent cover was used during the measurements in order 
to maintain constant hydration of the sample. Typically, 
128 scans were acquired at 4 cm–1 resolution, two levels of 
zero filling, and 25°C. For each spectrum, the background 
was acquired on the empty attenuated total reflectance 
plate.
Magnetic HFt preparation  
and transmission electron  
microscopic analysis
Magnetite (or maghemite) was incorporated into the HFt-
MSH using a method described elsewhere.34 Briefly, iron 
incorporation experiments were carried out at 65°C on 
1 mg/mL HFt-MSH samples in 5 mM Hepes–NaOH at a pH 
of 8.5. Solutions of FeSO4 dissolved in 0.5 mM HCl were 
used as an iron source. During the course of the experi-
ment, the reaction vessel was kept at 65°C under a positive 
nitrogen pressure, and pH was maintained dynamically at 
8.5 with 100 mM NaOH using an automatic titrator (Titrino; 
Metrohm AG, Herisau, Switzerland). Solutions of FeSO4 
15 mM and H2O2 5 mM were added simultaneously at a 
constant rate (0.5 mL/minute) using two peristaltic pumps. 
The theoretical iron loading factor was 4500 Fe(II)/protein. 
The protein and iron contents in the samples containing the 
magnetic nanoparticles were assessed by means of native 
electrophoresis on 1% agarose gels and inductively-coupled 
plasma atomic emission spectroscopy.
HFt-MSH-enclosed magnetite/maghemite samples, 
in PEGylated or non-PEGylated form (0.1 mg/mL) were 
negatively stained (0.1% of trehalose into 1% ammonium 
molybdate) on glow discharge-activated carbon-coated 
grids.35 Samples were viewed under a Philips CM100 electron 
microscope (Eindhoven, The Netherlands) at 80 kV . Digital 
images were recorded using a MegaView II slow scan camera 
at a primary magnification of 92,000×.
Protein structure analysis and modeling
The atomic structure of HFt was downloaded from the 
  Protein Data Bank (http://www.pdb.org).36 Protein structure 
visualization and modeling of the PEG chains, MSH peptide, 
and Gly/Ser-rich linker were performed using Insight II 
software (Accelrys Inc, San Diego, CA).
Fluorescent labeling of proteins
HFt-PEG and HFt-MSH-PEG solutions (2 mg/mL) were 
incubated with 1 mM of 5(6)-carboxytetramethylrhodamine 
N-succinimidyl ester (λex 552 nm, λem 575 nm; Thermo 
Scientific, Milan, Italy) in phosphate-buffered saline for 
2 hours at pH 7.5 and room temperature, with stirring in the 
dark. Subsequently, the samples were filtered, dialyzed, and 
exchanged with H2Odd and phosphate-buffered saline, using 
30 kDa Amicon Ultra-15 centrifugal filter devices to remove 
excess reagents. The samples were sterile-filtered and stored 
at 4°C in the dark. The number of dye molecules linked per 
protein was determined by absorbance spectroscopy, in 
accordance with the manufacturer’s instructions, applying 
the Beer-Lambert law. Briefly, the measurement was carried 
out using a 0.1 cm path length quartz cuvette at room 
temperature. The concentration of bound dye was calculated 
using the following equation: c(dye) = A 552 nm/(εmax × d), where 
εmax is 80,000 for rhodamine dye. The protein concentration 
is obtained in the same way from its absorbance value at 
280 nm, using an ε of 25,900 and 18,910 M–1 cm–1 for HFt-
MSH and wild-type HFt, respectively. Because rhodamine 
shows some absorption at 280 nm, the measured absorbance 
A280 was corrected for the contribution of this dye (correction 
factor = 0.34).
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Cell culture and confocal microscopy  
on tumor cells in vitro
The murine melanoma B16F10 cell line of C57BL/6 
(H-2b/H-2b) origin (ATCC, Manassas, VA) as well as human 
colorectal carcinoma HT29 cell line (ATCC) were cultivated 
in RPMI-1640 medium (Institute of Molecular Genetics, 
Prague, Czech Republic), supplemented with 0.05 mg/mL 
gentamicin, 2 mM L-glutamine, 1 mM sodium pyruvate, 
0.05 mM 2-mercaptoethanol, and 10% heat-inactivated fetal 
calf serum (Gibco, Grand Island, NY), at 37°C in a 5% CO2 
humidified atmosphere.
B16F10 melanoma or HT29 human colorectal carcinoma 
cells in suspension (1 × 106 cells/100 µL) were incubated 
with fluorescent wild-type HFt, HFt-PEG, or HFt-PEG-MSH 
in H-MEMD culture medium. The HFt nanoparticle solu-
tions (100 µL) were added to 100 µL of cell solution. The 
final concentration of HFt nanoparticles was 0.007 mg/mL. 
The controls received only addition of medium without 
HFt   nanoparticles. The cells were incubated at 37°C in 5% 
CO2 for 10 and 60 minutes. After incubation, the cells were 
fixed in 3.7% formaldehyde for 30 minutes and then washed 
three times with Dulbecco’s phosphate-buffered saline. 
The cell nuclei were stained using Draq5. The confocal 
microscopy apparatus comprised a confocal laser scanning 
system (1-  photon) Olympus FV1000 with an IX 81 inverted 
microscope, a Hamamatsu C9 100/13 EM-CCD digital 
camera, and an imaging analysis program (Flowview 10; 
Olympus, Tokyo, Japan). Confocal microscopy was per-
formed at 20× and 40× original magnification and all images, 
obtained using FluoView FV1000 software (Olympus), were 
background-subtracted and normalized to maximal intensi-
ties of the fluorescent HFt nanoparticles. Uptake of HFt 
nanoparticles by the cells was assessed from the average of 
the percentages of positive cells in three randomly evaluated 
fields per sample at 20× magnification, using four samples 
for each type of treatment and cells.
In vivo administration of HFt 
nanoparticles and confocal evaluation
Male C57BL/6 mice aged 7–8 weeks were purchased from 
AnLab (Prague, Czech Republic) and housed in conventional 
conditions in our experimental animal facility, and adapted 
to the local conditions over 10 days with a standard diet 
and access to water ad libitum before inoculation with the 
melanoma cells. The mice were intradermally/subcutaneously 
inoculated in the lower back with 1 × 106 B16F10 melanoma 
cells per mouse suspended in 0.1 mL of culture medium. Ten 
days after inoculation with the melanoma cells, the animals 
developed bulky tumors at the site of injection (5–7 mm 
diameter). Under general anesthesia, slow intracardiac 
injection of 0.1 mL of the experimental fluorescent wild-type 
HFt or HFt-PEG-MSH (0.5 mg) solution was performed. The 
animals were maintained for one hour under observation for 
possible secondary effects after awakening. The mice were 
sacrificed 24 hours after inoculation. A skin flap including 
the tumor and a liver sample were harvested. A thick 
tumor section, a sample of skin, and a thick liver section 
were mounted on a large coverglass for direct observation 
of rhodamine fluorescence in the tissue by confocal laser 
scanning microscopy (excitation filter 530–550 nm) at 
40× original magnification, as described earlier.
Effect of HFt nanoparticles on immune 
cells in vivo
Healthy mice were sacrificed 24 hours after injection of the 
HFt nanoparticles. Their spleens were collected and gently 
dissociated through a nylon mesh in H-MEMD medium 
to prepare single cell suspensions, and splenocytes were 
not gradient-separated to collect all leukocytes. Complete 
blood samples were pretreated with ACK lysing buffer to 
lyse the erythrocytes before specific staining. Leukocytes 
were characterized by fluorescence-activated cell sorting 
analysis using an antibody against the CD45 common marker. 
CD69 positive cells were evaluated by gating the leukocyte 
population into granulogates, lymphogates, and monogates, 
respectively, on an FSc–SSc plot.
The experiments had the approval of the ethics committee 
at the Institute of Microbiology, according to the Animal 
Protection Act of the Academy of Sciences of the Czech 
Republic and the European Convention for the Care and Use 
of Laboratory Animals.
Plasma stability and circulation time  
of HFt nanoparticles
The stability of the iron-containing wild-type HFt and HFt-
MSH-PEG in mouse plasma was determined by size   exclusion 
chromatography. Samples of the HFt nanoparticles (0.20 mL, 
10 mg/mL) were incubated at 37°C with mouse plasma 
(1.8 mL) and collected as follows. Samples were withdrawn 
at hours 1, 6, 18, 24, and 48, centrifuged at 13,000 rpm for 
30 minutes, and loaded onto a Superose 6 gel filtration col-
umn connected to a GE Healthcare FPLC system Unicorn 
Akta purifier in phosphate-buffered saline at a flow rate of 
0.5 mL/minute. The presence of intact HFt nanoparticles was 
determined by simultaneously following the protein signal 
(absorbance at 280 nm) and the iron cluster (absorbance 
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at 405 nm), and calculating the area of the elution peaks 
typical of HFt 24-mers using Unicorn 5.01 software (GE 
Healthcare).
To evaluate the circulation time of the wild-type HFt 
and HFt-MSH-PEG nanoparticles, 0.1 mL of nanoparticles 
(1.0 mg) was injected into the tail veins of the mice. Blood 
(0.5 mL) was collected from each mouse before injection and 
at 3 minutes and 1, 3, 6, and 24 hours following   injection. 
Plasma was obtained by centrifugation of the fresh blood, 
containing heparin as an anticoagulant, at 13,000 rpm for 
45 minutes. Presence of HFt nanoparticles was quantified by 
Western blotting using both anti-MSH and anti-HFt   antibodies. 
  Polyacrylamide gel electrophoresis was   performed under 
denaturing and reducing conditions. Plasma was diluted 2× in 
sample buffer to prevent precipitation of serum proteins dur-
ing boiling. Diluted samples were then boiled for 5 minutes. 
Thereafter, 12% sodium dodecyl sulfate gels were run at 150 V 
for one hour. Gel electrophoresis proteins were transferred to 
polyvinyl difluoride membranes in transfer buffer (25 mM Tris-
HCl, 192 mM glycine, and 20% methanol, pH 8.3) at 100 mA 
for 45 minutes. Thereafter, membranes were blocked overnight 
at 4°C in 10% blocking reagent (  Boehringer Mannheim, Lud-
wigshafen, Germany). Subsequently, the membranes were 
incubated in 1% gelatin in Tris-buffered saline with a rabbit 
monoclonal antibody, anti-HFt (Abcam, Cambridge, UK) or a 
rabbit polyclonal antibody anti-MSH (Abcam). Both antibod-
ies were diluted 1000×. Primary antibodies were detected with 
horseradish peroxidase-conjugated rabbit antigoat IgG (Sigma-
Aldrich), and signals were visualized using a luminol-based 
chemiluminescent substrate designed for use with peroxidase-
labeled reporter molecules (LumiGlo®, KPL, Gaithersburg, 
MD) and Kodak Scientific Imaging Film (Eastman Kodak 
Company, Rochester, NY).
Results and discussion
Our main aim was to obtain an HFt-based construct that 
was shielded against nonspecific uptake by human cells and 
possessed a satisfactory circulation time in the bloodstream, 
which is a key property for in vivo applications. Derivatization 
using an inert and uncharged material such as PEG appeared 
to be an adequate strategy, both to reduce nonspecific cell 
binding and prolong the circulation time in serum. Based 
on previous reports, we set the size of the PEG molecules 
at 5 kDa.37 Following observation of the three-dimensional 
structure of human HFt, we decided to link PEG molecules 
to the thiol groups of the cysteine residues, given that the 
location of the exposed cysteine thiols on the surface of HFt 
is such that their PEGylation is not expected to interfere 
with subsequent derivatization of the N-terminal region, and 
given that HFt has a relatively small number of cysteine side 
chains on the external surface (two per subunit, ie, 48 for 
the whole assembly), compared with other solvent-exposed 
reactive groups (ie, amines and carboxylates), allowing us 
to have tight control over the number of PEG molecules 
conjugated to the HFt shell. To obtain covalently bound HFt 
construct-PEG complexes, the HFt constructs were reacted 
with functionalized maleimide-PEG 5 kDa.
The PEGylation reaction was performed using both 
wild-type HFt and the HFt construct containing the 
  melanoma-binding peptide sequence, α-MSH, genetically 
linked to the N-terminal region of HFt (HFt-MSH). The 
α-MSH peptide was chosen for a number of reasons. Short 
amino acid polymers (peptides) have a target-binding ability 
comparable with that of larger molecules, such as antibodies. 
Due to their small size, peptides are also ideal for multiple 
modifications of nanoparticle constructs and generation 
of pluripotent nanoparticles.38 Moreover, α-MSH binds to 
melanocortin receptors and, in particular, is a potent agonist 
of the melanocortin type 1 receptor (MCR1, overexpressed 
by many melanoma cells39) and binds to MCR1 with high 
affinity (IC50 0.21 nmol/L).40 Importantly, more than 80% 
of human metastatic melanoma samples have been found to 
display MCR1.41 Melanoma metastases are very aggressive, 
with a patient survival time of 3–15 months on average, and 
are the actual cause of mortality in patients with melanoma.42 
Therefore, the development of a system containing a targeting 
peptide able to bind melanoma metastases is of critical 
importance. Gold nanoparticles linked onto an analogous 
synthetic peptide were recently shown to have reasonably 
selective tumor localization compared with the nonspecific 
PEGylated form.43 However, because of the synthetic peptide 
origin, a very long and expensive procedure including peptide 
synthesis and chemical conjugation to the nanoparticles 
was required to obtain the final constructs. In our case, a 
simple cost-effective genetic engineering approach was 
used to link the α-MSH peptide (SYSMEHFRWGKPV) to 
the N-terminus of the HFt subunit, resulting in production 
of an HFt assembly containing 24 peptide copies. This HFt 
nanocage should, in principle, have increased affinity for the 
corresponding receptor compared with a molecule containing 
a single peptide unit (ie, the multivalence effect).
Each α-MSH peptide was spatially separated from 
the HFt subunit N-terminus by an inert and flexible Gly/
Ser-containing sequence linker. The length of the linker was 
designed based on analysis of the crystal structure of human 
HFt (PDB ID: 3AJO) and modeling of PEG molecules of 
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the chosen length to guarantee sufficient exposure of the 
targeting α-MSH peptide on the HFt external surface in the 
presence of PEG.
The yields of purified recombinant HFt-MSH and 
wild-type HFt from E. coli cultivation were in the ranges 
of 150–200 mg/L and 80–100 mg/L, respectively. The 
purification procedures used for HFt-MSH were much easier 
and faster with respect to HFt, and allowed us to obtain large 
amounts of pure and fully assembled protein within two 
days. The integrity of the HFt-MSH N-termini after protein 
purification and PEGylation was checked by MALDI mass 
spectrometry, which confirmed that the full-length amino 
acid sequence corresponding to the α-MSH peptide plus 
linker was present at the protein N-termini (Supplementary 
Figure S1). The mass spectra also highlighted the presence of 
PEG molecules linked to the cysteine residues of the protein 
(Supplementary Figure S2). Effective protein PEGylation was 
also monitored by Fourier transform infrared spectroscopy. 
Typical PEG signals relative to the (CH2–O–CH2) moiety 
and to the methylene stretching modes were detected only in 
the PEGylated HFt-MSH-PEG sample (see Supplementary 
Figure S3). In turn, amide bands at 1952 cm–1, typical of 
alpha helical structures, were almost super imposable on the 
native and PEGylated proteins.
After incorporation of magnetite/maghemite, the HFt-
MSH was analyzed by transmission electron microscopy, 
which showed that the HFt-MSH construct retained the 
ability of wild-type HFt to encapsulate magnetic iron and 
adopted the expected spherical cage-like structures with an 
external diameter of 13 ± 2.1 nm, typical of wild-type HFt 
(Supplementary Figure S4). As expected, the shape of the 
PEGylated HFt constructs did not appear to be perfectly 
spherical due to the flexibility of the PEG molecules present 
on the protein surface (Figure 1).
The magnetic properties of the HFt-MSH construct, 
evaluated by zero-field-cooled and field-cooled magnetization 
experiments (data not shown), were very similar to those 
previously reported for magnetite/maghemite nanoparticles 
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Figure 1 (A) Transmission electron microscopic image of magnetite/maghemite-containing HFt-MSH-PEG showing the metallic core (black) surrounded by the HFt shell 
(white). Inset: 2.5× magnified image, the scale bar represents 32 nm. (B) Size-exclusion chromatography and (C) dynamic light scattering profiles of HFt-MSH before (solid 
line) and after (dotted lines) the PEGylation reaction. 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide.
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enclosed in different ferritin cages.37 The HFt-MSH sample 
had a loading factor of 3900 metal atoms per protein 
molecule, as assessed by inductively coupled plasma analysis. 
This number is close to the maximum loading capacity of the 
protein, which is around 4000 atoms, and is relevant in view 
of the potential uses of HFt-based nanoparticles as magnetic 
resonance imaging agents, which require a high enough 
amount of iron atoms to provide a detectable signal.
Size exclusion chromatography and dynamic light 
scattering was performed to estimate the diameter 
and polydispersity of the PEGylated (HFt-PEG and 
HFt-MSH-PEG) samples. All samples were found to be 
quite monodispersed in solution (Figure 1B and C, and 
Supplementary Figure S5). Both experiments indicate that 
non-PEGylated and PEGylated samples have a significant 
difference in size (mean diameters 13.0 and 20.0 nm, 
respectively), implying elevated efficiency of the PEGylation 
reaction.
The aforementioned results indicate that, even after the 
addition of more than 30 amino acids to the N-terminal region 
of each protein subunit, HFt maintained the characteristic 
24-mer cage architecture, the ability to incorporate iron 
derivatives, the ability to undergo pH-induced dissociation 
and reassembly (Supplementary Figure S6), and high thermal 
stability. Indeed, HFt-MSH showed even higher thermal sta-
bility than wild-type HFt in circular dichroism experiments 
(Supplementary Figure S7).
The PEGylated derivatives, HFt-PEG and HFt-MSH-
PEG, were labeled with NHS–rhodamine, an amine-reactive 
fluorescent reagent that absorbs green visible light (552 nm) 
and emits orange-red visible light (575 nm). This permitted 
us to trace the localization of our constructs on the surface 
of and inside the target cells (see below). Rhodamine-labeled 
HFt nanoparticles were purified from free dye by dialysis 
and centrifugal filter devices. The number of dye molecules 
linked per protein was determined to be about 0.9/subunits 
(22.0/protein cage) for both HFt-PEG and HFt-MSH-PEG 
by absorbance spectroscopy (see Materials and methods 
section).
To investigate the targeting efficacy of the HFt-MSH-PEG 
constructs and to verify whether we succeeded in reducing 
their nonspecific binding to cancer cells, we   compared their 
ability to target B16F10 melanoma cells versus a different 
type of cancer cells.
Cells incubated at different times with either 10 nM 
rhodamine-labeled wild-type HFt, HFt-PEG, or HFt-MSH-
PEG were imaged using confocal microscopy. In agreement 
with previous findings,25,36 wild-type human HFt bound both 
melanoma cells and human HT29 colon carcinoma cells, as 
shown by the presence of a number of red particle clusters on 
the cell surface (Supplementary Figures S8 and S9), indicat-
ing that it was recognized nonspecifically by different cell 
types. Conversely, none or very few of these clusters were 
observed in the case of HFt-PEG (Figure 2B), indicating that 
derivatization with PEG molecules effectively shields the HFt 
molecule from its receptors on melanoma cells. Remarkably, 
in the presence of HFt-MSH-PEG, large numbers of clusters 
of small red particles were easily detected on both the surface 
and in the cytoplasm of melanoma cells (Figure 2A) whereas 
none or very few fluorescent clusters were present inside or 
on the surface of HT29 cells (Figure 2C). The relative per-
centages of cancer cells positive to binding/internalization 
of HFt-MSH-PEG or HFt-PEG were evaluated in three ran-
domly evaluated fields per sample at 20× magnification, and 
the average values are reported in Figure 2D. Four samples 
were examined for each type of construct and cells.
These results indicate that the α-MSH targeting moiety 
effectively overcomes PEG masking and allows the HFt-
MSH-PEG constructs to recognize their target melanocor-
tin receptors on melanoma cells specifically and that PEG 
molecules of the chosen length provide the HFt-MSH-PEG 
constructs with an effective shield against recognition by 
other cell types. It is important to point out that the HFt-
MSH-PEG derivatives were also able to be internalized by 
the target melanoma cells, which is a necessary property 
for potential therapeutic application. In contrast, in the lone 
previous report on HFt derivatives bearing an RGD peptide 
as a targeting moiety, evidence of construct internalization 
was not provided.26 Given that internalization is likely to be 
mediated by interaction of the exposed α-MSH ligand with its 
cognate melanocortin receptor, the choice of tumor selector 
appears to be an essential factor to take into account in the 
rational design of nanoparticles for targeted delivery.
Finally, we performed a series of in vivo experiments 
using melanoma-bearing mice. Twenty-four hours after 
intracardiac injection, confocal microscopy performed on 
freshly harvested skin flaps, including tumor tissue, demon-
strated marked accumulation of HFt-MSH-PEG constructs 
inside the melanoma tissue in all the skin layers examined, 
ie, epidermal, dermal, subdermal, and subcutaneous (Figure 3 
and Supplementary Figure S10). Only an occasional weak 
signal from a few cells in the dermal/subcutaneous layers 
was observed, most likely from phagocytes. In contrast, 
wild-type HFt did not accumulate at tumor sites (Figure 3). 
As expected, some accumulation of HFt-MSH-PEG con-
structs was found also in Kupffer cells in the liver, but not 
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in hepatocytes. This result indicates that the HFt-MSH-PEG 
constructs have significantly higher target selectivity with 
respect to the previously reported HFt construct bearing an 
RGD peptide as the targeting moiety, accumulation of which 
was far greater in the liver than in the target glioma tumor.24 
To our knowledge, this is the only HFt-based construct that 
has been previously studied in vivo.
We then investigated the in vitro plasma stability and 
in vivo circulation time of the HFt-based nanoparticles. For 
the plasma stability test, a size exclusion chromatography 
experiment using a GE Healthcare FPLC system Unicorn 
Akta purifier was undertaken to monitor the presence of intact 
nanoparticles after incubation in mouse plasma. The data 
reported in Table S1 demonstrate that both wild-type HFt 
and HFt-MSH-PEG nanoparticles have very high in vitro 
plasma stability, because they undergo very little degradation 
over 48 hours of incubation in mouse plasma (about 92% 
and 98% of intact protein, respectively). Clearance of HFt 
and HFt-MSH-PEG nanoparticles from the blood was inves-
tigated in vivo using Western blot analysis in healthy mice. 
HFt-MSH-PEG nanoparticles showed a significantly higher 
concentration and longer residence time in blood compared 
with wild-type HFt nanoparticles (Figure 4). In particular, 
HFt was absent after one hour, in accordance with previously 
reported data indicating clearance of HFt from the circula-
tion in the 10–60 minutes following injection.28 In contrast, 
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Figure 2 Laser-scanning confocal microscopy of mouse B16F10 melanoma (A and B) and human HT29 colon carcinoma (C) cells after one hour of incubation with   
HFt-MSH-PEG (A and C) or HFt-PEG (B) nanoparticles. Both types of nanoparticles were rhodamine-labeled. Clusters of HFt-based nanoparticles with rhodamine 
fluorescence appear in red. Original magnification 40×. Scale bar corresponds to all images. (D) Cell binding/internalization percentages assessed from the in vitro results. 
Average of positive cells in three randomly evaluated fields per sample at 20× magnification (four samples for each type of treatment and cells). 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide.
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HFt-MSH-PEG showed significantly greater persistence in 
the circulation, being clearly visible for up to 6 hours and still 
detectable at 24 hours. Such differential blood kinetics are 
likely to contribute to the different biodistribution patterns 
observed for wild-type HFt and HFt-MSH-PEG.
In addition, very preliminary in vivo tests were per-
formed to investigate the effect of HFt nanoparticles on 
immune cells. No significant changes in the percentages 
of immune cells present at 23–24 hours after in vivo 
administration of the nanoparticles in the murine model 
were observed. However, we found increased expression 
of the early activation marker, CD69, on all the leukocyte 
populations investigated (see Supplementary Figure S11). 
Activation by both HFt nanoparticles resulted to be gener-
ally higher in the spleen than in the blood, especially in the 
granulogate cells. Interestingly, activation of all groups of 
cells following administration of wild-type HFt was stron-
ger than that induced by HFt-PEG-MSH   nanoparticles. 
Although very preliminary, our results suggest that HFt 
nanoparticles exert some direct functional effects on leu-
kocytes, possibly due to activation of phagocytosis, and 
that PEGylated HFt-MSH-PEG constructs have a weaker 
primary immunological stimulatory effect than wild-type 
HFt, supporting the hypothesis that PEG molecules are an 
effective shield for the HFt protein. However, it is worth 
bearing in mind that while α-MSH is completely con-
served in humans and mice, murine HFt is not identical to 
the human homolog. Therefore, nanoparticles containing 
human HFt are expected to be more immunogenic in the 
mouse than in humans.
The high target selectivity, plasma stability, and a long 
circulation time observed for the HFt-MSH-PEG nano-
particles developed in this experiment indicate that these 
constructs can be exploited to develop HFt derivatives for 
application in the diagnosis and/or treatment of melanoma. 
For example, the HFt-MSH-PEG nanoparticles could be 
further engineered by chemically conjugating reactive groups 
on the external surface using temozolomide or dacarbazine by 
means of reversible cross-linkers, the bonding of which with 
the drug would be expected to be broken in the cytoplasm. 
Additionally, the internal cavity of HFt could be loaded with 
cisplatin, which has been shown to have cytotoxic activity 
when incorporated within commercial horse apoferritin,25 or 
64Cu, which may be used for detection by PET.24 HFt-based 
constructs bearing these functionalities are currently being 
developed in our laboratory.
Figure 3 Laser scanning confocal microscopy on the freshly removed tumor (A), liver (B), and skin (C) 24 hours after intracardiac administration of rhodamine-labeled 
HFt-MSH-PEG (top) and wild-type HFt (bottom) nanoparticles. Melanoma B16F10 developed in mouse C57BL/6 with a 6 mm diameter. Original magnification 20×. 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide.
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Further, the rational design of HFt-based nanoparticles 
as reported here is amenable to exploitation for selective 
delivery to a large number of different cell types, provided 
that a suitable targeting moiety is available. Targeting 
  moieties that can be loaded onto the HFt nanoplatform 
include not only peptides, which can be genetically linked 
to the protein, but also molecules endowed with reactive 
groups, which can be conjugated with reactive amino and/
or carboxylate groups exposed on the HFt surface.
To evaluate the actual potential of targeted HFt-PEG 
  constructs for clinical application and to assess whether 
PEGylation affects the main routes of ferritin protein 
excretion in the body (ie, the kidney and/or liver),33 further 
in vivo studies, including biodistribution in other relevant 
tissues, body clearance, toxicity, immunological effects, and 
the immunogenicity of our constructs will be performed.
Conclusion
In this work, we developed a rationally designed, genetically 
engineered, and chemically modified HFt-based multifunc-
tional nanoplatform (HFt-MSH-PEG). These constructs were 
extensively characterized by taking advantage of an array of 
physicochemical techniques, and their targeting selectivity 
and plasma stability were assessed by in vitro and in vivo 
experiments, HFt-MSH-PEG were recognized and internal-
ized specifically by melanoma cells, but not by other human 
tumor cells or mouse tissues (except for expected uptake by 
dedicated phagocytes), and were present for up to 24 hours in 
the bloodstream. The high target specificity of HFt-MSH-PEG 
is determined by the following: choice of a selective targeting 
moiety, namely the α-MSH peptide, sufficiently exposed on 
the protein surface because of the presence of a peptide linker 
which binds receptors expressed only by melanoma cells and 
to a lesser extent by melanocytes; controlled modification 
of the HFt protein surface with PEG molecules of appropri-
ate length, which mask the whole construct, except for the 
targeting α-MSH peptide, from its   physiological receptors; 
and significant reduction in nonspecific r  ecognition and 
reduced uptake by the   reticuloendothelial and   mononuclear 
phagocytic systems.
The targeting strategy adopted in this work to produce 
HFt-MSH-PEG constructs can be implemented to develop 
HFt-based PEGylated nanoparticles containing targeted 
molecules for different cells and tissues. Further modification 
with cytotoxic and/or imaging agents would be required to 
produce molecules amenable to theragnostic applications. 
Selective nanoparticle accumulation at the sites of disease, as 
observed in this work, would allow tumors to be visible in the 
earlier stages, enabling improved diagnostic possibilities, and 
contribute to reduction of toxic side effects in normal tissue, 
thereby increasing the efficacy of chemotherapy. Indeed, we 
expect that the HFt functionalization strategy presented here 
will help overcome many of the current difficulties in the 
use of ferritin-based assemblies for in vivo applications and 
advance towards the development of protein-based nanoplat-
forms for effective diagnostic and therapeutic applications.
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Figure S1 (A) MALDI-MS spectrum of the native HFt-MSH-PEG trypsin digests. Peaks corresponding to the MSH and linker amino acid sequences at the protein N-termini 
are indicated with red arrows. (B) MALDI-MS/MS spectrum of the m/z 1056.5 peak reported in (A).
Notes: The fragmentation sites along the peptide (SYSMEHFR) backbone corresponding to the observed peaks are indicated by arrows, and the arrow direction indicates 
the charge-retaining portion. Peaks corresponding to the expected masses for the y and b ions are indicated by the relative ion name. 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide; MALDI, matrix-assisted laser desorption ionization; 
MS, mass spectrometry.
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Figure S2 MALDI-MS spectrum (range 2200–3000 m/z) of the native HFt-MSH (A) and HFt-MSH-PEG (B) trypsin digests.
Notes: Peaks matching to the protein sequences are reported. The m/z 2504.3 peak corresponds to the KPDCDDWESGLNAMECALHLEK sequence and it is expected to 
react with and bind to PEG-maleimide molecules due to the presence of two cysteine residues. From mass analysis, a decrease of the peak corresponding to this peptide was 
observed, but a heavier peak at about 12,000–13,000 m/z did not appear, likely because of poor flying ability due to the conjugation with PEG molecules. 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide; MALDI, matrix-assisted laser desorption ionization; 
MS, mass spectrometry.
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Figure S3 Attenuated total reflectance-Fourier transform infrared spectra of apo-HFt-MSH (red) and PEGylated apo-HFt-MSH-PEG (blue). 
Notes: The spectra have been obtained on fully hydrated samples in attenuated total reflectance mode on a ZnSe plates at 4 cm-1 resolution and 25°C. Spectra were 
subtracted by the contribution of the clean and empty attenuated total reflectance plates. Details of the low frequency region highlight the presence of the PEG (CH2–O–CH2) 
stretching modes at 1098 cm-1 (top spectrum) in the PEGylated apo HFt-MSH. The contribution of the PEG (H–C–H) stretching modes is also manifest in the increased 
absorbance at 2978 cm-1 in the PEGylated protein (top spectrum). 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide; MALDI, matrix-assisted laser desorption ionization.
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Figure S4 TEM image of magnetite/maghemite-containing HFt-MSH showing the metallic core (black) surrounded by the HFt shell (white). Inset: 2.5× magnified image, scale 
bar 32 nm.
Abbreviations: HFt, human protein ferritin; MSH, melanocyte-stimulating hormone peptide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1504
Vannucci et alInternational Journal of Nanomedicine 2012:7
150
100
50
m
A
u
2
8
0
 
n
m
0
05 10 15 20 25 30 35
0.1 11 0 100 1000 10000
B
A
Size (nm)
Volume (mL)
0
2
4
6
8
10
12
14
16
R
e
l
a
t
i
v
e
 
i
n
t
e
n
s
i
t
y
Figure S5 (A) Size exclusion chromatography and (B) dynamic light scattering profiles of HFt before (solid line) and after (dotted lines) the PEGylation reaction. 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol.
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Figure S6 Size exclusion chromatography profiles of HFt-MSH before (solid line) and after (dotted lines) the pH jump experiment (see Material and methods section).
Abbreviations: HFt, human protein ferritin; MSH, melanocyte-stimulating hormone peptide.
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Figure S7 Thermal denaturation of HFt (open circle) and HFt-MSH (black circle). 
Notes: Spectra were recorded at 222 nm in 0.1 quartz cuvettes. Protein concentration was 1 mg/mL in H2Odd. 
Abbreviations: HFt, human protein ferritin; MSH, melanocyte-stimulating hormone peptide.
Figure S8 Laser-scanning confocal microscopy of mouse B16F10 melanoma cells after 10 (top) and 60 (down) minutes of incubation with HFt rhodamine-labeling. 
Notes: Clusters of HFt-based nanoparticles with rhodamine fluorescence appear in red. Original magnification 40× (left) and zoom 3× (120×, right) were used. 
Abbreviations: HFt, human protein ferritin; MSH, melanocyte-stimulating hormone peptide.
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Figure S9 Laser scanning confocal microscopy of human HT29 colon carcinoma cells after 10 (top) and 60 (down) minutes of incubation with HFt rhodamine-labeling. 
Clusters of HFt-based nanoparticles with rhodamine fluorescence appear in red. 
Note: Original magnification 40× (left) and zoom 3× (120×, right) were used. 
Abbreviation: HFt, human protein ferritin.
Figure S10 Melanoma and skin.
Notes: Representative image from a Z series of 46 images, 0.8 µm space, taken at the border of the tumor.  The specific uptake of HFt-MSH-PEG nanoparticles by the tumor 
cells but not by the surrounding tissue was evident in all images. The tumor was initially sectioned to be leveled to the surrounding tissue and allow effective evaluation of both 
tissues on the same layer (confocal microscopy, 20× original magnification, nanoparticles fluorescence in red, numbers indicate areas that were selected for further imaging 
analysis, first image). 
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide.
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Figure S11 Percentages of CD69-positive cells in two gated populations of leukocytes (granulogates, lymphogates, and monogates) from peripheral blood and spleen cells, 
evaluated at 23 hours after administration of HFt-nanoparticles in healthy mice (three animals per group). 
Abbreviation: HFt, human protein ferritin.
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Table S1 Stability of HFt and HFt-MSH-PEG nanoparticles in human plasma
Time (hours) HFt HFt-MSH-PEG
% of intact protein 
Initial
 
100
 
100
1 93 99
6 92 98
18 92 98
24 92 98
48 92 98
Abbreviations: HFt, human protein ferritin; PEG, polyethylene glycol; MSH, melanocyte-stimulating hormone peptide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1509
Selective targeting of melanoma